Tuesday 26th March
Wednesday 27th March
11.00 - 11.30
Various multi coordinate, blood-based gene interrogation approaches evaluate tumor biomarkers such as ctDNA, mRNA, miRNA released by tumor cells, which contain extensive representations of variants present in the tumor, allowing precise non-invasive monitoring of cancer in real time. Gliotrack™ offers coverage on all relevant molecular biomarkers, and is beneficial for patients with suspected glioma/glioblastoma and who are unfit for biopsy, diagnosed glioma patients, to monitor disease progression and detect recurrence at the earliest.
11.45 - 12.15
Corina van den Hurk
Chemotherapy-induced alopecia is a side effect with high impact for many cancer patients. In Europe scalp cooling has been used to prevent hair loss for over a decade and is increasingly being applied worldwide. A registry containing data of more than 5,000 scalp cooled breast cancer patients shows varying success rates depending on type and dose of chemotherapy. Determinants of efficacy as well as safety and cost-effectiveness will be discussed.
12.30 - 13.00
Maggie’s helps... ...anyone affected by cancer. So at Maggie’s you can talk to and get support from a range of professionals. Our 21 Centres are staffed by Cancer Support Specialists, Benefits Advisors, Nutritionists, therapists and Psychologists, all providing support in whichever way best suits you. Emotional support to families is discussed and the unique way Maggie’s helps.
13.15 - 13.45
Professor Farzin Farzaneh
Advanced Therapy Medicinal Products (ATMPs) for achievement of deeper and longer lasting immune mediated cancer remission
Cell and gene based therapy of cancer is making major improvements to the treatment of cancer. The development of new strategies for the development of chimeric antigen receptor T cells, genetically modified cancer cell vaccines and therapeutic cancer vaccines for the specific induction of cellular immunity will be described.
14.00 - 14.30
Mr Richard Steyn
The UK Lung Cancer Coalition (UKLCC) was set up in 2005 with the founding ambition of tackling poor survival outcomes and, specifically to double 5-year survival by 2015, which has now effectively been achieved (in England). The UKLCC is now calling for governments, commissioners and the health care community to re-double efforts and work together to raise 5-year rates to 25% by 2025 across the UK.
14.45 - 15.15
Dr. Omar Milhem
A presentation on the use of Proteoglycan Replacement Therapy as a treatment to help rebalance the Hair Growth Cycle following completion of Chemotherapy treatment. The role that proteoglycans play in helping improve the recovery of hair loss as a result of Chemotherapy treatment.